Part 2 - A phase II study of Anti-PD1 (nivolumab) therapy as pre- and post-operative therapy in metastatic renal cell cancer (ADAPTeR)
Samra Turajlic The Royal Marsden NHS Foundation Trust, London, UK discusses the second part of A phase II study of Anti-PD1 (nivolumab) therapy as pre- and post-operative therapy in metastatic renal c...
Author: kidneycancer
Added: 04/02/2019
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts
More News: Cancer | Cancer & Oncology | Foundation Trusts | Kidney Cancer | Renal Cell Carcinoma | Study | Urology & Nephrology